FDA clears Medtronics new left-heart leads

Justine Varieur Cadet | | Health Imaging | Screening
The FDA has approved Medtronic’s Attain Ability Plus and the Attain Ability Straight left-heart leads for use with cardiac resynchronization therapy (CRT) devices in treating heart failure patients.

The two new dual-electrode leads are the latest offering in a line of left-heart lead options that fit through the Attain Select II sub-selection catheter delivery system and navigate patient vein anatomies during the CRT implant procedure, according to the Minneapolis-based company.

The product is immediately available in the U.S.

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.